At Africa Health ExCon 2026, EVA Pharma showcased its expanding African footprint, including new legal entities in Kenya and Nigeria and partnerships with major pharmaceutical companies. The company, which produces more than 1 million medicines daily across internationally accredited facilities, operates two research centres bringing first-of-its-kind capabilities to the Middle East and Africa, including mRNA research and AI-driven biological product development. EVA Pharma has set a goal of enhancing access to quality insulin for 30 million people annually in limited-resource settings by 2030, alongside ongoing efforts to build vaccine and API manufacturing capacity for the continent.
Read more:
https://www.evapharma.com/events/africa-health-excon-2026-494
